UK BNF 40% DISCOUNT ends JAN 16, 2015

JANUARY 2015 VIEW IN BROWSER Welcome to the BNF January eNewsletter. This month's newsletter features an update on the use of lipid-regulating drugs for the primary and secondary prevention of cardiovascular disease. You'll also find information on new legislation on drug impairment while driving, attempting to drive, or being in charge of a vehicle. And, your last chance to buy a copy of BNF/C at 40% off! Read on for more details. Kind regards, BNF Team IN THIS ISSUE Significant changes More > Changes to Appendix 3 More > News More > How to purchase BNF More > Monthly price update reminder More > Drug Safety Update More > Feedback on our eNewsletter More >

Significant changes This month's changes to the clinical content of BNF publications are described in two parts: • BNF & BNFC update should be read by all users of the BNF or BNFC • BNF update should be read by all users of the BNF • BNFC update should be read by all users of the BNF for Children BNF and BNFC update Drugs and Driving - New Legislation A new offence of driving, attempting to drive, or being in charge of a vehicle with certain specified controlled drugs in excess of specified limits, is expected to come into force on 2nd March 2015. This offence is an addition to the existing rules on drug-impaired driving and fitness to drive, and applies to two groups of drugs - commonly abused drugs, including cannabis, cocaine and ketamine, and drugs used mainly for medical reasons, such as opioids and benzodiazepines. Amphetamines are also expected to be added to the legislation later in 2015. For more information, see Drugs and Driving in General Guidance, and Drugs and Skilled Tasks in General Guidance. BNF update Lipid Modification The section on Lipid-regulating drugs has been updated with recommendations from NICE clinical guideline 181 (Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease) and the Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3) 2014. For more information, see section 2.12. Other changes To review other changes in the BNF, click on changes. BNFC update To review changes in BNFC, click on changes. return to top

Changes to Appendix 3: Cautionary and advisory labels The following products from BNF and BNFC in the Appendix 3 list of products and their labels have been updated: : AS Saliva Orthana - Concerta XL - Eldepryl - Elvanse - Equasym XL - Ibrutinib - Imbruvica - Lysdexamfetamine - Medikinet - Methylphenidate - Methylphenidate MR - Ritalin - Selegiline - Zelapar return to top News Pharmaceutical Press Winter Sale The Pharmaceutical Press book sale will come to an end on 16 January - so this is your last chance to buy the BNF or BNFC at a 40% discount. See here for more details, and order your copy now.